COPD and Asthma Drugs Market by Disease (COPD and Asthma) by Medication Class (Combination Drugs, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics and Others) and by Geography (North America, Europe, Asia-Pacific, LAMEA) - Global Opportunity Analysis and Industry Forecasts, 2014-2022

  • ALL22851
  • 120 Pages
  • October 2016
  • Pharmaceuticals

Asthma is a chronic respiratory disease blocking the airways of the lungs because of the inflammation, mucus production, tighten of muscles. The general symptoms are coughing, wheezing, shortness of breath and/or chest tightness and majorly these symptoms are closely related to the physical activity. There are different types of asthma, exercise-induced bronchoconstriction(EIB), allergic asthma, occupational asthma, childhood asthma. Chronic Obstructive Pulmonary Disease (COPD) is also respiratory disease which causes obstructions and difficulty in breathing, the primary cause of COPD is tobacco smoking and chemical flumes, dust, air pollution are minor causes of the disease. Major symptoms are long lasting cough, mucus that comes out along with cough, shortness of breath.

The world COPD and asthma drugs market is expected to reach $50,359 million by 2022, growing at a CAGR of 3.7% from 2016 to 2022. Increase in prevalence of asthma and COPD, increase in world ageing population, technological advancement in the treatment of asthma and COPD, growth in initiatives implemented by the government and non-government associations for rise in health awareness play a pivotal role in the growth of the global COPD and asthma drug market. Stringent government regulatory requirement for the approval of COPD and asthma drug, patent expiry of branded hamper the market growth.

The world asthma and COPD drugs market is segmented based on disease and medication class and geography. On the basis of disease, the market is segmented into COPD and asthma. Based on medication class, the world asthma and COPD drug market is segmented into combination products, short acting beta agonists (SABA), long acting beta agonists (LABA), inhaled corticosteroids (ICS), leukotriene antagonists (LTA), anticholinergics and others. And geographically, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

Key benefits

  • The study provides an in-depth analysis of the asthma and COPD drug market with current trends and future estimations to elucidate the imminent investment pockets in the market.
  • The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the asthma and COPD drug market, by medication class, helps in the treatment of asthma and COPD diseases.
  • Competitive intelligence highlights the business practices followed by leading market players across various geographic regions.
  • Key market players within the asthma and COPD drug market are profiled in this report and their strategies are analyzed thoroughly, which predicts the competitive outlook of global asthma and COPD drug market.
  • Key market segments
  • The world COPD and asthma drug market is segmented by medication class, disease and geography.


  • COPD
  • Asthma


  • Combination Products
    • Seretide/Advair
    • Symbicort
    • Relvar/Breo Ellipta
    • Flutiform
    • Dulera
    • Others
  • Leukotriene Antagonists (LTA)
    • Singulair
    • Others
  • Inhaled Corticosteroids (ICS)
    • Qvar
    • Pulmicort
    • Aerospan
    • Flovent
    • Others
  • Anticholinergics
    • Spiriva
    • Others
  • Short Acting Beta Agonists(SABA)
    • ProAir
    • Ventolin
    • Others
  • Long Acting Beta Agonists (LABA)
  • Others


  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • U.K.
    • France
    • Germany
    • Italy
    • Rest of Europe
    • Asia-Pacific
    • Japan
    • China
    • India
  • Rest of Asia-Pacific
    • LAMEA
    • Latin America
    • Middle East
    • Africa


  • GlaxoSmithKline (GSK)
  • Novartis AG.
  • Merck & Co.
  • Abbott Laboratories.
  • Boehringer Ingelheim.
  • AstraZeneca.
  • Roche Holding AG
  • Teva Pharmaceutical Industries.
  • Vectura Group
  • Pfizer

Other players in the value chain include (profiles not included in the report)

  • Mylan
  • Aerovance Inc.
  • Alkermes Inc.
  • Almirall SA
  • Genentech Inc.
  • Sepracor, Inc.
  • Skyepharma plc
Please Select Format

Enquiry About Report

Need More Information

Contact us
+ 1-800-910-6452
+91 20 66346066
--- or ---



Global General Medicine Education Publishing Market (Type, Geography) Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Opportunities, Segmentation, Forecast (2013-2020)

General medicine is a branch of medicine that deals with diagnosis and treatment of diseases associated with internal organs. It is also called as Internal Medicine. General medicine education market has shown substantial growth due to the adoption of internal medicine as a career option by medical students.

April 2018| $5370 | Pre Book Price:$4699

Cancer Vaccine Market Global Scenario, Market Size, Outlook, Trend and Forecast, 2015- 2024

Cancer vaccines are biological response modifiers. These vaccines work by stimulating or restoring the immune system�s ability to fight against infections and diseases. It is used either as stand-alone therapies ...

April 2018| $4995 | Pre Book Price:$4371

World Active Pharmaceutical Ingredient (API) Market - Opportunities and Forecasts, 2014 - 2020

Increase in Abbreviated New Drug Applications (ANDA) over the past years has fostered the demand for API market. Furthermore, Indian companies making increased entries related to Drug Master File (DMF) ...

April 2018| $5370 | Pre Book Price:$4699

Anterior Uveitis Asia-Pacific Market Research Report, 2014 - 2020

Anterior uveitis is an eye inflammation that involves middle layer of the eye specifically, iris (colored part of the eye) and ciliary body (adjacent tissue). Untreated anterior uveitis results in ...

April 2018| $2850 | Pre Book Price:$2494

Nanomedicine Asia-Pacific Market Research Report, 2014 - 2020

Nanomedicine is the applied branch of nanotechnology. Application of nanomedicines ranges from nonmaterial to nanoelectronic and in the near future, it could possibly expand to molecular nanotechnology. Biological, pharmaceutical and ...

April 2018| $2850 | Pre Book Price:$2494

Autoimmune Disorders Treatment Asia-Pacific Market Research Report, 2014 - 2020

Graves disease, Multiple sclerosis, Myasthenia gravis, Rheumatoid arthritis, Pernicious anemia and Systemic lupus erythematosus are the most prevalent types of autoimmune disorders. The prevalence of autoimmune diseases is high in ...

April 2018| $2850 | Pre Book Price:$2494

2018 © Copyright Big Market Research

View Pricing >>